Because men with lung cancer have poorer survival, we examined the effect of sex on the prognostic value of the eighth edition of tumor, node, metastases staging (TNM). Men had worse 5-year survival within each stage. This suggests that outcomes in TNM staging should be quoted separately for men and women to improve the prognostic, research, and clinical accuracy. Introduction: Nonesmall-cell lung cancer (NSCLC) has disproportionately negative outcomes in men compared with women. The importance of the relationship between sex and tumor, node, metastases (TNM) staging system remains unknown. The objective of this study was to investigate the effect of sex on NSCLC survival for each stage in the eighth edition of the TNM staging system in NSCLC. Patients and Methods: Two cohorts treated surgically with curative intent between 2000 and 2010 were analyzed. The primary cohort was from Australia with a second population set from the Surveillance, Epidemiology, and End Results (SEER) database. Univariate and multivariate analyses of putative and validated prognostic factors were undertaken to investigate sex-dependent prognostication with detailed analyses of sex differences in each TNM stage. The primary outcome was disease-specific survival (DSS) at 5 years. Results: Inclusion criteria were met by 555 patients in the Australian cohort, 335 men (60.4%) and 220 (39.6%) women; and 47,706 patients from the SEER cohort, 24,671 men (51.7%) and 23,035 women (48.3%). Five-year DSS was significantly worse for men in multivariate analyses for the Australian (hazard ratio [HR], 1.44; 95% confidence interval [CI], 1.04-1.98; P ¼ .026) and SEER (HR, 1.24; 95% CI, 1.20-1.28; P < .001) cohorts. Detailed analysis of TNM stage sex differences revealed a consistent pattern of men having worse survival than women across stages in both cohorts. Conclusion: The poorer survival in men with NSCLC presents research and clinical communities with an important challenge. This study's findings suggest that for men and women diagnosed with NSCLC, and managed surgically, stage-specific outcomes should be quoted separately and consideration to a rapid prognostic score with sex combined with staging as a key element.
Introduction
Recognition of the importance of integrating sex analyses for clinically accurate research is gaining significant momentum globally. From the 2001 Institute of Medicine's Report that declared "Every cell has a sex" 1 to the work of the European Commission Horizon2020, which has put in place a requirement for funding that ".describe how sex and/or gender analysis is taken into account in the projects context." 2 The importance of sex differences is being realized throughout research communities. What is driving this is an increased awareness of the differences between men and women in diseases and response to treatment. [3] [4] [5] The work of
Oertelt-Prigione and Regitz-Zagrosekwork points out that sex and gender differences occur across public health, cardiovascular disease, gastroenterology, hepatology, nephrology, hematology, neurology, and pharmacokinetics and dynamics. In addition they highlight that examining sex differences is not about women, but about the unbiased comparison between men and women, and in understanding these differences a more accurate scientific approach is taken resulting in improved health outcomes for men and women. 5 Gendered Innovations from Stanford University outlines in its case study in osteoporosis that although men account for nearly one-third of all osteoporotic fractures, osteoporosis continues to be seen as a disease of elderly women, driving biased diagnostic and treatment approaches, with criteria to identify and treat men not well established. As a result of identifying this bias researchers have identified medical conditions and treatments with a higher correlation with osteoporotic fractures in men than women and in so doing improved diagnosis and treatment for men, as well as for women. 6 Lung cancer, with the highest global cancer mortality rate, 7 like many other diseases, shows sex differences with worse outcomes in men than women, with global age-standardized mortality rates (ASRs) for men of 30.0 and women of 11.1. 7 The American Surveillance, Epidemiology, and End Results (SEER) database shows a mortality rate ratio of being male of 1.82, 8, 9 and hazard ratio (HR)
for being male of 1.17, after controlling for age and stage. 9 These population-based findings, corroborated by GLOBOCAN, 10 imply a significant contribution of sex 9 in lung cancer outcomes.
Sex differences in cancer mortality have been reported as early as 1947. 11, 12 More recently, Cook et al analyzed data, 1977 Cook et al analyzed data, -2006 from the SEER database for solid and hematologic malignancies and reported that the ASR was greater in men. 8, 9, 13 Survival rates for many cancers showed sex differences persisting after adjustment for age, TNM stage, and grade of disease. 9 The United Kingdom "Excess Cancer Burden in Men" report, 2013, showed that men had a 37% higher risk of death from cancer than women. 14 The TNM staging system defines the anatomical extent of disease and is the most important prognostic algorithm for lung cancer. It was first described in the 1940s by Dr Pierre Denoix, a surgical oncologist, as a system for documenting the extent of a cancer according to TNM descriptors. 15 The Union Internationale Contre le Cancer published their first TNM cancer staging system in 1968, 16 with the eighth edition being implemented in January 2017. 17 The purpose of TNM staging, then, as now, was to aid treatment planning, prognostication, assess the result of treatment, facilitate communication among health professionals and to patients, and contribute to research design. 18 Despite known sex-related differences in lung cancer outcomes, 19 there is a paucity of data on how staging classifications perform for men and women and in turn approaches for implementing findings. 20, 21 Notwithstanding the importance of staging and the importance of sex on health outcomes, the effect of sex on nonesmall-cell lung cancer (NSCLC) staging remains largely undefined. In this study we investigated the effect of sex on survival within each stage of the eighth edition TNM 22, 23 staging system for NSCLC in a surgical cohort.
Patients and Methods

Data Source
Data were collected from 2 surgical units in Australia and the SEER database, for patients who underwent surgery from 2000-2010. The Australian data set was the primary most comprehensive data set, with the SEER data set providing a population-level validation series.
Study Population
The Australian Data Set. A retrospective analysis of a prospectively maintained Australian multisite surgical database was undertaken. The data were enriched with reviews of electronic and hard-copy clinical records. All patients who underwent surgical resection with curative intent of histologically confirmed NSCLC were included. Exclusion criteria included neoadjuvant therapy, follow-up <3 months, and extensive disease precluding curative intent. Ethics approval was obtained from the Human Research Ethics Committee at St Vincent's Hospital and the Peter MacCallum Cancer Centre.
The SEER Data Set. The SEER database is an American National Cancer Institute project, which maintains data on cancer incidence, morbidity, and mortality in the United States of America. SEER*-Stat version 7.1.0 24 was used to extract data for patients who had undergone a resection of histologically confirmed NSCLC. Cases were excluded if intent was not curative, survival was unknown, presence of more than 1 primary cancer, or pathological details were insufficient to determine eighth edition TNM stage. 22, 23 Ethics requirements of the SEER project were met.
Clinical Data
The Australian Data Set. Sex Differences in Staging NSCLC Using TNM Eighth Edition visceral or parietal pleural invasion, and nodal metastases. Primary tumor location, size (mm), and additional tumor nodules were documented according to pathologic evaluation of the resection specimen. Pathologic TNM stage was determined according to the seventh TNM revision and converted to eighth edition.
22,23
The SEER Data Set. Data extracted included sex, age at diagnosis, histology, tumor stage, tumor size, duration of follow up, TNM seventh revision classification, survival status, and SEER causespecific death classification.
Statistical Analysis: Main Outcome Measures
All statistical analyses were conducted using IBM SPSS Statistics version 25.0. Advice on the analytic approach was sought from an experienced data analyst.
The Australian cohort's sample size was pragmatic on the basis of available data. The rule of 10 events per predictor variable was used as a guide to ensure sufficient number of events per predictor for each Cox model. 29 Descriptive statistics summarized patient characteristics. The independent t test was used to compare continuous patient and tumor characteristics according to sex, with Pearson's c 2 test used to compare nominal patient, tumor, and staging variables according to sex. The KaplaneMeier method was used to calculate estimates of disease-specific survival for the aggregated cohorts and separately for men and women. The primary end point was cancer-specific mortality, calculated from the time of pathologic diagnosis to the date of death. Patients with survival >5 years were censored at 5 years.
Univariate and multivariate analyses were performed to assess the prognostic importance of sex. Cox proportional hazard regression was used to assess the prognostic importance of sex (male and female) at 1 and 5 years adjusting for prognostic factors described in the IASLC staging manual, 30 specifically pathologic stage (eighth edition: IA1, IA2, IA3, IB, IIA, IIB, IIIA, IIIB þ IIIC, IVA þ IVB), ECOG-PS (0 or 1), ethnicity (Asian, non-Asian), age (meancentered and rescaled, 5-year increase in age from average age), smoking (never and ever/current if more than 100 cigarettes consumed), and histology (adenocarcinoma, non-adenocarcinoma), were examined for association with survival for the overall cohort and according to sex. For the SEER and Australian cohorts M1a, M1b, and M1c were combined as were stage IIIC and IIIB because of a small number of cases. Cox proportional hazard regression models were used to assess the prognostic importance of sex within each stage in the SEER cohort using unadjusted and adjusted models, the latter of which included age and histology. The size of effect was quantified as per Olivier et al. 31 Alpha was set at 0.05 (2-tailed) for all analyses. No adjustment was made for multiple testing because this study was exploratory in nature.
Results
Patients
Five hundred fifty-five patients were included in the analysis: 335 men (60.4%) and 220 women (39.6%) from the Australian Cohort. Seventy-five patients were excluded, 52 because of nonanatomic resection, 19 because of insufficient follow-up, and 4 because of Table 1 ). Five-year outcome data were available for 10,495 patients (22%). More men had tumors with squamous-cell carcinoma histology and more advanced pathologic TNM stage compared with women. There was no significant difference between men and women with respect to age.
Survival
The Australian cohort's 5-year survival was 59.3%, which was statistically greater for women (68.9%) than for men (53.9%; P < .001). Five-year survival for the SEER cohort was 62.1%, statistically greater for women (65.6%) than men (55.2%; P < .001, Figure 1A ). Median survival was 31 months overall, and 29 and 34 months for men and women, respectively.
Multivariate Analysis
Male sex was independently prognostic for disease-specific mortality in the Australian cohort after adjustment for other putative prognostic factors, with a HR of male sex of 1.44 (95% confidence interval [CI], 1.04-1.98); P ¼ .026 (Table 2 ). For SEER sex remained a significant variable with the HR of male sex of 1.24 (95% CI, 1.20-1.28); P < .0001 (Table 2) .
Sex-Specific Stage Difference
Because of small numbers in the Australian cohort only the direction of effect can be described, which was consistent with women having survival superior to men at all stages from IA2 onward at 5 years (Table 3 and Figure 2 ).
For the SEER cohort, there was a significant difference in stagespecific survival between men and women, with men having a Table 4 shows that unadjusted and when adjusted, for age and histology, sex differences persisted within 
Discussion
Sex differences have been identified as affecting many physiological, pathophysiological, and pharmacological outcomes, 32 including in cancer, 9 with the Institute of Medicine (IoM) noting in 2001 that "every cell has a sex" 1pp4 in their landmark report "Exploring the biological contributions to human health: does sex matter?". 1 Abdoli et al examined cancer mortality in populationlevel Swedish data that showed that men had a higher ASR than women for all-site cancers. 33 Men with melanoma in the United
Kingdom have 11% lower 10-year survival than women, 14 a finding reproduced by Downing et al, who reported a HR of 0.67 for women with melanoma at 10-year survival. 34 Furthermore, a
United Kingdom study reported 10-year survival for all cancers combined for men was 39%, and 51% for women. The authors conceded that some of this discrepancy was driven by women with breast cancer with a good prognosis. The finding of worse outcomes in men was not uniform, with bladder cancer in women having 10% lower 5-year survival than men, in part because of women being diagnosed at a later stage.
14 A recent German study of 164,996 colorectal patients showed poorer outcomes in men. However, unlike our findings, sex-based survival differences decreased with increasing age and more advanced disease. 35 Although several groups report results conflicting with the aforementioned studies, many of these studies suffer from limitations of small cohorts 36, 37 or are older studies. 38, 39 Lung cancer is consistent with this pattern as described by Deng et al, in Guangzi, China 1971 to 2005, where men had a higher mortality rate of 2.43 compared with women at 1.16 per 100,000. 40 The Moffitt Cancer Center undertook a retrospective review of trends in survival for patients with NSCLC (1986-2008). They reported that men had worse outcomes than women, controlling for age, stage, smoking, and histology (HR, 1.24 [95% CI, 1.09-
1.41])
. 41 This is consistent with the IASLC Lung Cancer Staging Project for NSCLC, 42 which reported a median survival difference of 24 months with a poorer prognosis in men. These findings align 43 The IASLC Staging Project undertook recursive partitioning analyses for the seventh edition TNM, which showed outcomes for women were superior to men (stage IA disease) when age, sex, and histology were included. 42 Confounding factors might contribute to observed sex differences including that women are more likely to have adenocarcinoma histology, 44 with some adenocarcinoma subtypes shown to be associated with a better prognosis. 45 Our study showed that women were more likely to have adenocarcinoma, but importantly when histology was controlled for, women continued to have better survival than men. Asian ethnicity is known as a favorable prognostic factor in NSCLC, 46 and the incidence of NSCLC has been observed to be 3 times higher among Asian women, 47 suggesting that ethnicity could be a factor in the observed sex differences, in part because of the greater likelihood of the tumor types having targetable mutations. 48 Although ethnicity can be prognostic, sex is a factor in all patients irrespective of ethnic background and, as seen in our study when controlled for ethnicity, sex remained a significant prognostic factor. Smoking and associated comorbidities could also be confounding factors. Our study showed in the Australian cohort that men had higher rates of smoking than women, however, when controlling for smoking, male sex remained a prognostic factor associated with shorter survival consistent with published findings. 43 Although individual comorbidities were not specifically controlled for, ECOG-PS was available for the Australian cohort, and hence took All  47706 42269  38171  34786  33427  32624  IA1 Male  213  203  194  189  187  184  IA1 Female  380  374  368  356  352  348  IA2 Male  3310  3181  3062  2966  2895  2853  IA2 Female  4341  4239  4135  4026  3951  3893  IA3 Male  2914  2721  2566  2454  2369  2307  IA3 Female  3219  3114  2983  2864  2789  2740  IB Male  4235  3936  3663  3457  3345  3263  IB Female  4250  4044  3825  3661  3549  3469  IIA Male  1487  1333  1218  1147  1095  1083  IIA Female  1052  983  914  875  840  820  IIB Male  5254  4548  3919  3579  3409  3290  IIB Female  4039  3645  3246  2974  2813  2717  IIIA Male  4625  3720  2996  2643  2505  2421  IIIA Female  3610  3101  2575  2294  2130  2042  IIIB+C Male  1286  986  766  678  644  617  IIIB+C Female  984  789  627  556  512  479  IV Male  1356  899  688  594  552  536  IV Female  1160  878  697  615  578 into account the functional effect of comorbid disease, although it needs to be noted that ours was a surgical cohort and therefore selected for a better performance status. Our study showed men were more likely to have an ECOG-PS 1, consistent with published findings, 49 and despite this, showed that male sex remained a poor prognostic factor when adjusted for ECOG-PS. A further potential explanation for sex-based survival differences might lie in women undertaking health-seeking action earlier than men, a gendered factor, noting that gender refers to socially created attributes, whereas sex refers to biological and physiological attributes. 50 In our study, the tumors of women were more likely to be lower stage than those of men, suggesting more active healthseeking behavior. Regardless of this, women showed longer survival within each stage. Ball et al noted men were more likely to have larger tumors, suggesting later presentation, and men had a numerically worse prognosis. 51 Shugarman et al examined SEER
Medicare linked data (1995-1999) for evidence of sex differences in the receipt of timely and appropriate care for patients with lung cancer and reported that, among stage I and II patients, women were 25% less likely to receive timely surgical resection than men, 52 suggesting variances in timing of provision of care were unlikely to be a factor in the survival differences between men and women. Sex differences are not incorporated into TNM staging because it includes only tumor-related factors and anatomical effects from the tumor. The seventh edition of TNM classified sex as a host factor and recognized it provides additional information with respect to prognosis. 42 This iteration identified the possible inclusion of patient characteristics, such as sex, in future iterations of staging/prognostic scores. 30 And although for our study the eighth edition of TNM remains accurate for men and women, our data show that sex might cause stage migration because of the consistent differences in HR for men and women within each stage. Stage migration inevitably results in a lack of clarity as to how treatment should proceed, and as such, correcting for sex Although such models might represent a more accurate prognostic approach, they add a degree of complexity because of the number of factors required that might not be practical in real-world settings. Sex is an ever-present biological factor with implications in terms of disease natural history and response to treatment. As noted by the IoM report "every cell has a sex," 1 hence, rather than sex being considered a host factor, sex could accurately be recognized as a tumor factor. Furthermore, in recognizing the importance of sex in cell line and animal research the United States National Institutes of Health in 2016 implemented a policy requiring that sex be included as a biological variable in preclinical research. 54, 55 Wainer et al identified that the maximum standardized uptake value of fluorodeoxyglucose on PET scan was prognostic in men and not women with NSCLC, showing sex differences between the tumor cell metabolism of glucose, which correlated with survival. 56 These findings were further corroborated by Ippolito et al, who reported a higher glycolytic rate was associated with poorer survival in men but not in women with glioma, indicating sex differences at the tumor cell level. 57 Dougherty et al showed that tumor cells have a sexual dimorphism in so far as in adenocarcinoma cell lines from men and women had similar numbers of estrogen receptor a and b, but the male cell lines were not estrogen-responsive. 58 Yuan et al undertook a comprehensive characterization of molecular differences in cancer between male and female patients across 13 cancer types including NSCLC adenocarcinoma and squamous-cell carcinoma histology using the Cancer Genome Atlas. They reported that both NSCLC histologies showed an extensive sex-biased molecular signature for clinically actionable genes including epidermal growth factor receptor, serine/threonine kinase 11, and the dystrophin gene, 59 further showing sex differences at the tumor cell level. Our study has several limitations including its reliance on retrospective data. Retrospective data increases the risk of bias, which is a risk present in both populations. The risk in the SEER data also includes that although the numbers of cases are large it only represents 27% of the US population. For the Australian data set, it was a purely surgical data set and therefore biased toward earlier stage, fit for surgery patients. Although this study compared data from 2 different countries, importantly the findings were consistent, however, the Australian cohort analysis was underpowered, and the analyses failed to reach statistical significance. The small number of events likely contribute to this. In addition, the new staging system has more categories than the previous system, therefore requires greater numbers in each category for findings to reach statistical significance.
Conclusion
Despite limitations of retrospective data in this study, rarely is there a finding so consistently significant as the excess mortality observed in men with lung cancer. One of the challenges of this finding has been interpreting what it means in terms of underlying biology, etiology, and differences in clinical outcome, and how we implement the findings to improve patient outcomes. In addition, a further challenge with the current approach of not routinely disaggregating men and women is that the outcomes of any studied cohort will be dependent on the proportion of women in the cohort, which will skew results to the better prognostic end of the spectrum.
Because sex is a fixed host factor, unlike the other essential host factors of weight loss, performance status, and age, consideration could be given to incorporating or correcting for sex in staging to develop a simple and rapid prognostic score. This would allow for greater accuracy of prognosis and research design, particularly if supplemented with research into the effect of sex-disaggregated staging differences on treatment, clinical guidelines, and research protocols. Recognizing sex as an essential host factor and importantly also a tumor factor might result in the lung cancer community translating the survival benefit exhibited by women, thereby improving the accuracy of prognostication, research, and in turn possibly improved survival resulting from more tailored treatment paradigms.
Clinical Practice Points
It is well known that in the patients with NSCLC, men experience worse 5-year survival than women. Sex is considered an important variable in research and as such always included in multivariate analyses. However, this fails to answer the question as to what and why there are differences in survival between men and women with NSCLC. This research showed that although the new eighth edition TNM staging system holds true in men and women, that the 5-year survival of men is worse than women within each stage. Because of this finding this study recommends the IASLC reconsider the classification of sex from not only a host factor but also a tumor factor (because every cell has a sex), and that researchers and clinicians undertaking research from basic to clinical, ensure they recruit sufficient numbers of men and women to allow for significantly powered studies to compare the findings between the sexes. It is important that men and women are analyzed as separate populations, including within each stage, and that sex is not just included in the multivariate analysis because this does not answer the question as to whether there is a difference between men and women. This will ensure that we systematically address the causes of survival differences between men and women and guarantee the therapeutic and clinical guidelines are matched for the differing biology of each sex. Finally, incorporation of sex into a rapid prognostic score would allow for more accurate prognostication and reduce the heterogeneity currently seen in TNM staging.
Disclosure
The authors have stated that they have no conflicts of interest.
